The Federal Circuit ruled that a patent on a CAR-T treatment did not meet patent law's written description requirement. Jones Day and Irell & Manella are arguing for Bristol-Myers Squibb that the Federal Circuit has added judicial requirements to the statute that are virtually impossible for life sciences companies to meet.
June 14, 2022 at 06:44 PM
4 minute read
When the U.S. Supreme Court is faced with a challenging question of patent law, its instinct is often to request the views of the solicitor general, who in turn consults with the U.S. Patent and Trademark Office.
Bristol-Myers Squibb (BMS) already has those bases covered in its cert petition Tuesday seeking to restore a $1.2 billion judgment over a breakthrough cancer treatment.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
Gregory Castanias (left) of Jones Day and Henry Hadad of Bristol-Myers Squibb. (Photos: ALM and Courtesy)
